|

EGFR Antibody Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Sun Yat-Sen University Cancer Center1

Indications

  • Recurrent Nasopharynx Carcinoma1
  • Metastatic Nasopharyngeal Carcinoma1
  • Nasopharyngeal Cancinoma (NPC)1
  • Cancer1

Other1 trial

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.